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Abstract
Being the cause for significant amount of morbidities and mortalities, parasitic 
diseases remain the major challenge for the healthcare community due to the limita-
tions associated with the current chemotherapeutics. Drug discovery/invention can 
be achieved by collaborative efforts of biotechnologists and pharmacists for identi-
fying potential candidates and successfully turn them into medicine for improving 
the healthcare system. Although molecular medicine for disease intervention is 
still in its infancy, however, significant research works and successful trials in 
short span of time have made it broadly accepted among the scientific community. 
This chapter identifies different molecular medicine approaches for dealing with 
parasites that have been coming up on the horizon with the new technological 
advances in bioinformatics and in the field of omics. With the better understanding 
of the genomics, molecular medicine field has not only raised hopes to deal with 
parasitic infections but also accelerated the development of personalized medicine. 
This will provide a targeted approach for identifying the druggable targets and their 
pathophysiological importance for disease intervention.
Keywords: CRISPR/Cas9 system, monoclonal antibody, immune checkpoint 
inhibitors, nanomedicine
1. Introduction
Parasitic diseases remain the threat to global healthcare sector, with considerable 
mortalities and morbidities associated with these diseases. Combating parasitic 
infection relies mostly on conventional chemotherapeutic approaches; however, an 
exponential rise in the number of recrudescent cases, lack of vaccines and toxici-
ties issues associated with chemotherapies emphasized the need for the research to 
develop alternative strategies. It is noteworthy that emergence of drug resistance is 
not new; microbes have been evolving since ages, by knocking out one or the genes. 
In context of emerging drug resistance, World Health Organization (WHO) has 
warned for the upcoming “post-antibiotic era”, therefore, molecular medicine has 
surged. Molecular medicine is the application of gene and/or DNA based infor-
mation for therapeutic purpose. It involves the study of molecular mechanisms, 
identification of erroneous genetic and/or molecular pathways and development of 
molecular intervention with the aim to improve disease management.
This chapter provides an insight into how the anomalies in molecular 
pathways can be targeted leading to discovery of potential candidates for 
development of clinical medicine and innovative therapies to improve disease 
management strategies.
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2. Evolution of molecular medicine
The field of molecular medicine evolved over a period of time since the 
discovery of DNA (in 1953) and recombinant DNA technology. Another major 
breakthrough in 1975, when it was discovered that DNA can be read base by base 
through the sequencing technique. Later, in 1985, it was known that DNA can be 
amplified with PCR, and this was major achievement in the field of molecular 
diagnostics. This journey gained pace with the advent of automated DNA sequenc-
ing in 1987 that served as the background for the human genome project (HGP) in 
1990. The journey of HGP started the era of modern molecular medicine with the 
first successful gene therapy. In 1995, the success of unveiling the DNA sequence 
from the first model organism (Hemophilus influenzae) triggered the endeavor 
towards the completion of HGP. The completion of HGP (in 2000) and the free 
access to the human genome sequences provided the ground for the advent of 
omics era or post-genomic era (or functional genomics) [1].
This led to the use of increasing number of analytical platforms for DNA 
sequencing termed as the next generation sequencing platforms. Further, metage-
nomics approaches—omics and/or shot-gun approaches paved the way for the 
third-generation sequencing, that aimed to reduce the sequencing costs. These 
advances gained momentum with the computational approaches where synthetic 
biology has remarkably facilitated the DNA based analysis as well as the develop-
ment of models for drug testing.
In order to deal with the limitation of the existing chemotherapeutic approaches 
there remains an urgent need for the conversion of biomedical knowledge into clini-
cal application. Molecular medicine provides the opportunity to fill the gap between 
the basic research and the clinical application for the diagnosis, prevention and 
treatment of diseases. It involves the combinatorial application of pharmacology, bio-
medical and omics technologies for understanding and improving the molecular basis 
of the disease pathogenesis that will serve in designing disease intervention strategies. 
Development of molecular drug is a complex process that involves multidisciplinary 
effort including high throughput screening, chemical synthesis, modification, omics 
technologies, data mining, structure-based drug designing, phenotypic screening, 
target and lead identification and validation, etc. The development of molecular 
medicines involves following steps—first, the identification of target, potential 
tractability of target (i.e. identifying targets that are more druggable than others, 
depending upon their chemistry), establish genetic association of target with disease 
pathophysiology (some targets required for drug action may not necessarily associate 
with disease genetics) and validation of target (by establishing association of target 
with the disease development/persistence). Validation of target usually involves 
different molecular approaches to understand the role of target gene or protein in 
diseases pathophysiology. Overall, it is an interdisciplinary branch where recent tech-
nical advances have served as the milestone in gaining insight into the phenomenon 
of disease pathogenesis and development of innovative therapeutic measures.
Parasitic diseases are amongst the common infections in humans caused by pro-
tozoan and helminthic parasites. The causative agents, parasites, are diverse ranging 
from single celled protozoan to worms that be seen with naked eyes. Till the end of 
nineteenth century, parasitologists were mainly focused on understanding their life 
cycle; however, the concept took turn when some parasites were found to be associ-
ated with several human diseases that led to significant morbidity and mortality. 
Parasitic diseases are cosmopolitan, that may affect any part of world however, 
mostly the diseases are common in tropical countries, but tourism and migration 
can transmit them outside their geographical boundaries. The signs and symptoms 
of disease may not be obvious, and it may vary from mild abdominal pain to chronic 
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Diseases Causative agent 
(pathogen)
Transmitting agent 
(vector)
Manifestation Treatment options
Protozoan parasites
Leishmaniasis (visceral, 
cutaneous and 
mucocutaneous)
Leishmania species Sandfly (Phlebotomus & 
Lutzomyia species)
Fever, anemia, splenomegaly, 
lymphadenopathy; cutaneous forms 
manifests as skin lesions and ulcers
Liposomal amphotericin B, miltefosine, antimonials; 
fluconazole, itraconazole
Malaria Plasmodium species Female mosquito 
(Anopheles species)
Headache, fever, paroxysm, joint pain, 
anemia, jaundice; neurological symptoms in 
severe cases
Chloroquine, mefloquine, doxycycline
Chagas disease (American 
trypanosomiasis)
Trypanosoma cruzi Kissing bugs 
(Triatominae)
Fever, malaise, enlargement (liver, spleen, 
lymph nodes), sometimes skin nodules 
(chagoma); chronic stages affects the brain, 
heart and digestive system
Benznidazole, nifurtimox
Human African 
Trypanosomiasis
Trypanosoma brucei Tsetse fly (Glossina 
species)
First stage-intermittent fever, headache, 
swelling of lymph nodes, joint pain; second 
stage involves neurological symptoms
Pentamidine, suramin, fexinidazole, nifurtimox, 
eflornithine
Toxoplasmosis Toxoplasma gondii Oral route; transmitted by 
ingestion of parasite oocyst
Headache, fever, fatigue, muscle ache; skin 
manifestation includes erythema and roseola
Pyrimethamine, sulfadiazine, clindamycin, 
spiramycin
Trichomoniasis Trichomonas vaginalis Genital contacts Pain, itchiness/burning in genitourinary 
organs, urethritis, prostatitis (in males) 
while frothy, foul-smelling discharge, 
vaginitis (in females)
Metronidazole
Giardiasis (beaver fever) Giardia species Feco-oral transmission by 
ingestion of cysts
Chronic diarrhea, abdominal cramps, 
nausea and vomiting
Nitroimdazole, quinacrine, furazolidone, 
paromomycin
Cryptosporidiosis Cryptosporidium 
species
Oral transmission 
by consumption of 
contaminated water, 
undercooked food
Diarrhea, abdominal cramps, low-grade 
fever (in intestinal cryptosporidiosis); 
inflammation of nasal mucosa, cough, 
shortness of breath, hypoxemia(respiratory 
cryptosporidiosis)
Electrolyte replacement by rehydration therapy, 
nitazoxanide, azithromycin, paromomycin
Amoebiasis Entamoeba histolytica Feco-oral route Diarrhea, severe abdominal pain Amebicidals (metronidazole, tinidazole) and 
cysticidal agents (iodoquinol)
M
olecu
lar M
edicin
e
4
Diseases Causative agent 
(pathogen)
Transmitting agent 
(vector)
Manifestation Treatment options
Helminthic diseases
Roundworm infection (in 
murine)
Nippostrongylus 
braziliensis
Skin penetration Emphysema, loss of alveolar septa, lung 
hemorrhage
Tetramisole
Ascariasis (Roundworm 
infection, in human)
Ascaris lumbricoides Feco-oral route Fever, cough, weight loss, abdominal 
discomfort, intestinal ulcer accompanied 
with eosinophilia
Albendazole, mebendazole
Fasciolosis Fasciola hepatica Oral route, consumption of 
contaminated food
Acute phase marked by fever, nausea, 
skin rashes, abdominal pain; chronic 
phase manifests as jaundice, anemia and 
intermittent pain
Bromofenofos, triclabendazole, bithionol
Taeniasis Taenia species Consumption of 
undercooked pork or beef
Mild (abdominal pain and nausea) to no 
symptoms
Praziquantel, albendazole, niclosamide, mepacrine
Onchocerciasis (sub-
cutaneous filariasis)
Onchocerca species Blackfly (Simulium 
species)
Itchiness and bumps and depigmentation in 
skin to blindness
Ivermectin, moxidectin
Filariasis (lymphatic and 
serous cavity)
Wuchereria bancrofti 
and Brugia species
Blackflies and mosquitoes Edema with skin thickening and underlying 
tissues
Diethylcarbamazine citrate (DEC)
Neural angiostrongyliasis 
(eosinophilic meningitis)
Angiostrongylus 
cantonensis
Oral route; upon ingestion 
larvae in undercooked 
prawn, snails, slugs, frogs
Headache, fever, malaise, nausea, neck 
stiffness, varying degree of neurological 
dysfunctions
No specific treatment, supportive care helps reduce 
the severity of symptoms
Schistosomiasis Schistosoma mansonii Contact with fresh water 
contaminated with 
parasites (released from 
fresh water snails)
Abdominal pain, diarrhea, fever, cough, 
bloody stool and/or blood in the urine
Praziquantel, oxamniquine, metrifonate, artesunate, 
mefloquine
Trichinosis Trichinella spiralis Consumption of 
undercooked pork
Nausea, vomiting, fever, diarrhea, facial 
swelling
Mebendazole, albendazole
Table 1. 
Some parasitic diseases, their symptoms and treatment options.
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hepatomegaly and eventually death. Some parasitic infections are easily treated 
while others are not. In the light of the lack of vaccine for parasitic infection, proper 
prophylactic measures (proper hygiene, prevention of contaminated food, water, 
preventing consumption of undercooked food, use of bednets, insecticide spraying 
to prevent vector borne diseases, etc.) and active disease surveillance remains the 
key for disease elimination. Unfortunately, poor disease management strategies 
have made parasitic infections a global healthcare challenge. In this article it’s only 
possible to cover some important parasites (Table 1), for which research on molecu-
lar medicines are underway.
3. Molecular medicinal strategies and parasitic diseases
Parasitic infections (protozoan and helminthic infections) affect more than a 
quarter world population and cause chronic illness primarily in developing coun-
tries of world. These diseases affect the quality of life and treatment costs possess 
economic burden on families leading to viscous circle of poverty.
Molecular medicine is a broad field that includes insight into the molecular 
aspect of diseases. Recombinant DNA and cloning technologies are the conven-
tional tools for studying the disease associated molecular profiles. Recent technical 
advances have paved the way for utilization of several molecular strategies for treat-
ing infectious diseases. Molecular medicine aims to understand the molecular basis 
of disease pathogenesis and allows the utilization of the information in designing 
specific diagnostic, therapeutic and prophylactic options. Mainly molecular medi-
cine relies on two strategies—targeting genome and targeting signaling pathways, 
as targeted approach of disease management. Thus, it aims to improve the human 
health through the understanding of mechanism in human diseases.
3.1 Targeting genome
Apart from conventional approach of gene therapy (replacement of defective 
gene by exogenous DNA and editing mutated gene), recent technical advances 
have opened the arena for other strategies of manipulating the gene expression. 
Gene editing methods have gained limelight that involves the intrinsic molecular 
repair processes within the cell. The process of break repair in the DNA involves 
the homology-directed repair (HDR) and/or non-homologous end joining (NHEJ). 
The key step in gene-editing tool involves the precise introduction of double strand 
breaks. This process involves the use of engineered meganucleases, zinc-finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and the 
recent CRISPR/Cas system [2]. Further, short antisense oligonucleotides potentially 
serve as tools for abrogating the transcription of target gene. As compared to other 
genome editing methods CRISPR/Cas system using guide RNA has shown immense 
potential for future of molecular medicine.
3.1.1 Engineered meganucleases
Although there remains plethora of meganucleases to choose from, however, 
most commonly used meganucleases include the ZFNs that have DNA binding 
zinc finger protein domain and nuclease domain. Cys2-His2 zinc finger domain is 
amongst the most abundant types of DNA binding motifs in eukaryotes [3, 4]. The 
ZFNs work by binding to the DNA and cleaving it, which then undergoes repair by 
either homologous recombination or error-prone NHEJ [5]. Site-specific cleavage 
is induced by manipulating the ZFN complex to recognize two sequences that are 
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on either side of target site. Upon identification, cleavage of genome is induced by 
restriction enzyme (FokI), thus generating double stranded breaks in genome that 
can be used for editing the region.
TALEN has been introduced as an alternative to ZFNs. These are similar to 
ZFNs in using restriction enzyme that incorporates with the DNA binding domain, 
but are of different origin. Similar to ZFNs, these protein structures lead to the 
double stranded breaks in DNA for genome editing [6]. Unfortunately, there are no 
evidences for the use of the aforementioned meganucleases for the development of 
molecular medicine for parasitic diseases.
3.1.2 RNA-guided engineered nucleases (CRISPR-Cas9 system)
After the discovery of clustered regularly interspaced palindromic repeats 
(CRISPR) (in 1987) as a part of bacterial immune system against invading viruses. 
This strategy has potential application in editing human chromosome with great 
accuracy. It is RNA guided gene editing tool that uses Cas9 endonuclease for generat-
ing double-stranded breaks at loci of interest, which are then repaired via. HDR 
(using a template) or NHEJ or error-prone microhomology-mediated end joining 
(MMEJ) [7]. Thus, leading to mutation (insertion, deletion or substitution) with no 
or minimal damage to host genome. Since the sequencing of the parasite genome, 
CRISPR/Cas9 genome editing tool accelerated the molecular research in parasitology.
Genome editing in malarial parasite (P. falciparum and P. yoelii) has provided 
the ground for development of molecular medicine [8, 9]. CRISPR system of 
genome editing has played crucial role in understanding the drug resistance and 
pathogen survival thus, genome editing of the parasite genome holds promises 
to trigger host immune responses while preventing disease pathology. There are 
several studies for CRISPR/Cas9 analyses in T. gondii however, the most remark-
able one include the genome-wide screening that identified the genes involved in 
infection process [10, 11]. This has greatly accelerated the research to understand 
the parasite metabolic needs for survival and virulence, conversely, shedding light 
on dealing with drug resistance mechanisms. Similarly, CRISPR/Cas9 system 
for T. cruzi and T. brucei has facilitated functional studies of drug targets and/
or vaccine candidates [12, 13]. Genetic manipulation has always remained ardu-
ous for Leishmania however, CRISPR/Cas9 system has proven efficacy for rapid 
genome editing and understanding gene functions with therapeutic implication 
[14, 15]. Similarly, genome editing for T. vaginalis has been recently introduced 
with potential in vivo toxicity issues which has been dealt by using nucleofusion 
based transfection [16, 17]. Large-scale functional genomic screening cannot rely 
on conventional CRISPR/Cas9 approach thus, CRISPRi and CRISPRa approaches 
have gained significant attention for generating knock-in/knock-down libraries.
Genome editing using CRISPR/Cas9 system in Schistosoma mansoni eggs reduced 
the infection induced granulomas. Similarly, CRISPR/Cas9 mediated deletion of 
granulin gene from liver fluke (O. viverrini) significantly improved the disease symp-
toms [18]. This is just the start of the use of CRISPR/Cas9 system in parasitic diseases, 
it has broader potential in designing molecular medicine for disease intervention.
3.1.3 RNA interference (RNAi)
RNA interference is the approach of inhibiting the gene expression or translation 
by insertion of double-stranded RNA into the cells and/or organism that mediates 
targeted degradation of its homologous RNA. It can be done via. Short interfering 
RNA (siRNAs), micro RNA (miRNA) and piwi-interacting (piRNA). It mediates 
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gene silencing by forming RNA-induced silencing complex (RISC) that eventually 
degrades target mRNA. This unique ability of silencing target gene holds hopes for 
controlling parasitic infections.
T. brucei was the first protozoan parasite where RNAi based targeting of β-tubulin 
gene, changed parasite morphology [19]. Conversely, T. cruzi [20], L. donovani [21] 
and L. major [22] lack the essential protein (Ago-1) for suppressing the gene expres-
sion. RNAi mediated targeting of cathepsin B reduced the disease progression [23]. 
RNAi mediated targeting of topoisomerases and farnesyl pyrophosphate synthase 
have proven efficacy of RNAi based molecular medicine for disease intervention  
[24, 25]. Later, in 2011, RNAi target sequencing (RIT) identified several potential 
targets for genome-scale functional analyses which could potentially therapeutic 
targets [26]. RNA aptamers (synthetic RNA and DNA molecules) binds the target 
ligands (RNA/DNA) with high-specificity, and have been developed as pharmaceuti-
cally active compounds against T. brucei [27].
Malarial parasites lack the conventional RNAi pathway however, antisense 
oligodeoxynucleotides treatment (against parasite topoisomerase) has shown 
to significantly reduce the parasite multiplication [28]. Further, topoisomerase 
targeting antisense nanoparticles and chitosan-based nanoformulation have also 
been used to inhibit P. falciparum growth [29, 30]. Recently, synthetic siRNA 
targeting the β-actinin and cysteine protease served as potential molecular target 
for T. vaginalis infection [31]. Although still scrappy, better understanding of RNAi 
pathway in protozoan parasites is likely to revolutionize the molecular medicine due 
to its genome homeostatic potential.
RNAi based silencing of key genes involved in regulating the parasite survival 
and development have been potential candidates for therapeutics. Several miRNA 
have been known to regulate the nematode development and survival in the host 
microenvironment due to their immunoregulatory potential. These have also 
been crucial players of host-parasite interaction and have been used as diagnostic 
marker of infection. Nippostrongylus brasiliensis (rat parasite) was the first nema-
tode where RNAi was reported [32]. Much evidences for RNAi based knock-down 
studies have been seen in Schistosoma [33, 34], Brugia [35], Trichinella spiralis 
[36], Ascaris suum [37], Angiostrongylus cantonensis [38], Taenia saginata [39], 
Echinococcus [40], H. contortus [41] and Onchocerca volvulus [42]. Unfortunately, 
RNAi has not achieved the expected success in parasitic nematodes (schistosomes 
being an exception) [43]. This could be attributed to the lack of several key 
components of RNAi pathway [44]. Thus, targeted therapy with RNAi based 
approach (especially miRNA) is still in its infancy, in context of helminthic infec-
tions, that needs orchestrated support from the investors as well as the scientific 
community in order to stand alone as potential candidate for development of 
molecular medicine.
3.2 Targeting cells and signaling pathways
This area of molecular medicine remains the hottest area of research in the 
field of parasitic diseases after the World Health Organization (WHO) warning 
about the risk of post-antibiotic era. The search for novel therapeutic strategies 
intends to enhance pathogen killing by targeting regulatory molecules/pathways. 
Better understanding of disease immunobiology and cellular signaling will provide 
momentum to the identification of the pathways of therapeutic importance. This 
area of research towards the development of molecular medicine involves the use of 
genetically engineered antibodies, recombinant proteins, small molecules to alter 
signaling pathways, targeting the immunometabolic pathways, inflammasomes, etc.
Molecular Medicine
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3.2.1 Immunotherapeutic approach
Immunotherapy is use of biological substances (antigen/antibody, immunomodu-
lators administration) to regulate host immune system in order to fulfill prophylactic 
and/or therapeutic purpose. Immunotherapy aims to trigger the immune power by 
directly (antigen based or active immunotherapy) or indirectly (antibody based or 
passive immunotherapy) [45, 46]. This section describes various immunotherapeutic 
strategies of molecular medicine that have been reported for the parasitic diseases.
3.2.1.1 Recombinant proteins/cytokine therapy
Cytokines are the small molecular weight, chemical messengers that regulates 
the immune responses in autocrine and paracrine manner. There is plethora of 
evidences for the involvement of cytokines in determining the pathophysiological 
consequences. Recombinant protein (cytokine) based therapy aims to trigger T-cell 
immune responses and induces parasite clearance.
In T. cruzi infection, TGF-β (transforming growth factor-β) has been implicated 
to yield pathological consequences however, treatment with TGF-β receptor kinase, 
SB-431542, has shown to restrict the entrance of parasite in the cardiomyocytes and 
disease associated cardiomyopathy [47, 48]. Additionally, cytokine combination ther-
apy with recombinant IFN-γ and TNF-α has anti-parasitic potential [49]. In context of 
leishmaniasis, Murray et al. first proved the significance of targeting the cytokine, they 
showed that monoclonal antibody-based treatment targeting the IL-10 receptor (anti-
IL-10 receptor) instigated parasite clearance by inducing NO (nitric oxide) production 
[50]. Likewise, combination of recombinant IFN-γ therapy with conventional chemo-
therapy yielded promising results in controlling the disease pathology [51]. Not much 
has been reported about the cytokine-based therapy in other protozoan diseases.
Conversely, in helminthic infection, MAb (monoclonal antibody) based block-
ing of IL-4 and IL-10 has shown disease improvement by reducing parasitic burden 
and inducing TH1 immune responses [52]. Likewise, IL-4 based MAb therapy, in 
schistosomiasis, has shown to inhibit granuloma formation and hepatic fibrosis 
[53]. Similar findings of marked reduction in granuloma and hepatic fibrosis were 
reported upon treatment with Schistosoma eggs along with recombinant IL-12 
treatment [54]. Exogenous IL-25 based therapy has shown to potentially modulate 
intestinal functions by regulating IL-13 mediated STAT6 signaling in order to favor 
protective immune responses in intestinal nematode infection by N. brasiliensis [55]. 
Conversely, exogenous treatment with IL-13 and IL-25 triggered ILCs (innate lym-
phoid cells) responses and conferred protection against helminthic infections [56]. 
In schistosomiasis, IL-13 inhibitor, sIL-13Ralpha2-Fc has proved therapeutic benefit 
by preventing tissue fibrosis due to TH2 dominated inflammatory responses [49] .
The significance of exogenous cytokine therapy has also been underlined 
in trichiasis, where IL-33 is known to induce thymic stromal lymphopoietin 
that generates polarized TH2 responses to confer protection against intestinal 
nematodes [57]. While, IL-25 treatment instigated TH2 responses and restricted 
infection induced gastrointestinal inflammation [58], MAb based blockade of 
IL-10 ameliorated disease pathology. There are evidences for the IL-27 mediated 
suppression of T-cell proliferation thus IL-27 receptor (WSX-1) knock down 
improved the mucosal immunity [59]. The use of immune triggering cytokines 
(IFN-γ, IL-12, GM-CSF) and/or blocking immunoregulatory cytokines that pos-
sesses pathological consequences holds hopes for the development of molecular 
medicine. Thus, therapeutic potential of cytokine therapy can be exploited alone 
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and/or in combination with conventional chemotherapy opening up the avenues 
for improving treatment outcomes.
3.2.1.2 Immune checkpoint therapy
Immune checkpoint molecules are involved in regulating the T-cell activation 
and functions. The expression of these molecules is enhanced during chronic 
infections as a result of immune subversion, thus, therapeutically targeting these 
molecules has shown promising results in cancer and infectious diseases vaccines 
[60, 61]. Indeed, T-cell dysfunctionality or exhaustion is the key for impaired 
T-cell responses during chronic infections; exhaustion is marked by loss of IL-2 
production, reduced cytotoxicity, impaired production of pro-inflammatory 
mediators and reduced proliferative ability. The expression of multiple immune 
checkpoint molecules (PD-1, CTLA-4, LAG-3, Tim-3, TIGIT) remains the 
hallmark feature of exhausted cells; elevated expressions of these molecules 
are accompanied with progressive loss of T-cell functionality [62]. Immune 
checkpoint inhibitors have been novel strategy of reinvigorating the immune 
cell functions by abrogating the signaling by the immune checkpoint (or co-
inhibitory molecules).
A number of immune checkpoint molecules have been reported in leishmaniasis 
including—LAG-3, Tim-3, CTLA-4, PD-1, etc. that negatively regulates T-cell function-
ality [63–65]. MAb based blockade of PD-1 and LAG-3 in malaria triggered pro-inflam-
matory cytokine responses and relieved T-cell inhibition [66]. Likewise, therapeutically 
targeting LAG-3 and PD-L1 restored CD4+ T-cells functions, restored follicular helper 
T-cells, plasma cells eventually cleared the blood stage of Plasmodium [67].
Unfortunately, this strategy of immune checkpoint therapy has been in its 
nascent stage for parasitic infections, and has yet not been used for HAT, Chagas 
disease, gastrointestinal protozoans as well as helminthic infections.
3.2.1.3 Immune cells and stem cell-based therapy
Immune cell manipulation offers another fascinating approach of molecular 
medicine to fight with parasitic diseases, when other treatment options fail to 
provide protective immunity [68, 69]. Direct transfer of immune cells has been 
holding great promises for conferring protection against protozoan, bacterial and 
viral infections [70]. Adoptive T-cell transfer therapy using tumor-infiltrating 
lymphocytes is the best example to clinical success of cellular therapy [71].
DC (dendritic cell) based vaccination approach using parasite peptide (KMP-11) 
elicited TH1 responses, reduced parasite load and induced lymphocyte proliferation 
in leishmaniasis infection [72]. Similarly, vaccination with DC along with histone H1 
elicited pro-inflammatory responses (IFN-γ and IL-12), reduced the IL-10 and IL-4 
producing cells and induced polarized TH1 responses [73]. Atypical progenitor cells 
(IL-7R+ c-kit+ cells) from malaria infected mice are potent fighters against infec-
tion, while transplantation of these cells had similar effects in disease recovery [74].
After the success of direct administration of MSCs (mesenchymal stromal cells) 
and antigen specific T-cells stem cell therapy has recently budded in the field of 
infectious diseases. MSCs have been shown to be equally important in conferring 
resistance against P. berghei infection, by suppressing IL-10, reducing the regulatory 
T-cells population and inducing the production of IL-12 [75, 76]. Likewise, autolo-
gous transplantation of MSCs and myoblasts has shown to significantly reduce the 
ventricular dysfunctions [77].
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Transplantation of bone marrow mononuclear cells has marked effect on improv-
ing the inflammation and fibrosis in Chagas disease [78, 79]. Also, bone marrow 
transplantation holds promises for improving the quality of life in congestive heart 
failure due to Chagas disease [80, 81]. Adoptive immunotherapy in toxoplasmosis, 
by transferring CD8+ T-cells restricted parasite de-encystation; however, it failed 
to revert the T-cells exhaustion attributing to the short-lives of exhausted cells [82]. 
Further, MSCs therapy in toxoplasmosis has not been successful however, when used 
in combination with the spiramycin, pyrimethamine and folinic acid provided thera-
peutic benefits. Similarly, for coccidiosis, using adoptive transfer strategy, intraepi-
thelial lymphocytes (IELs) and CD4+ T-cells from interferon gamma knock out 
(Cryptosporidium parvum-infected) mice has shown to provide protection against 
infection in naïve mice [83]. Likewise, adoptive transfer of sporozoites pulsed-DCs 
upon co-culture with CD4+ and CD8+ T-cells reduced parasite burden [84].
In helminthic diseases, MSC based therapy have been proven to be efficacious for 
reducing Schistosoma japonicum induced liver injury by using MSCs culture super-
natant which inhibited macrophage activation by egg antigen. Macrophages primed 
with N. brasiliensis have been shown to clear the parasitic burden by neutrophil 
mediated mechanism of macrophage polarization [85] in strongyloidiasis. Filarial 
infections are associated with increased expression of Foxp3 expressing regulatory 
T-cells that impairs the CD4+ T-cell immunity. Regulatory T-cells targeted interven-
tion using antibodies against CD25, glucocorticoid-induced TNF receptor family-
related gene (GITR), provided cure for filarial infection [86]. In schistosomiasis, 
basophil depletion strategy has been shown to successfully ameliorate disease 
pathology and granulomatous lesions [87]. Similarly, in vivo DCs depletion has been 
an efficacious strategy to boost antigen specific T-cells expansion [88]. Antigen 
pulsed immune cell therapeutics has been extended to F. hepatica infection. DCs 
pulsed with parasite induces TH1 responses and has been a viable vaccination option 
that protects against disease associated hepatic damage [89]. Similarly, transfer of 
Hymenolepis diminuta pulsed bone marrow derived DCs cells ameliorated colitis 
pathology by IL-4 signaling [90]. Therefore, cell based therapeutic strategy serves as 
potential molecular medicinal approach for parasitic infections.
3.2.1.4 Immunomodulators
Immunomodulators are small molecular inhibitors of signaling pathways that 
serve as molecular medicine for disease intervention. Imatinib, an Abl/Arg tyro-
sine kinase inhibitor, induces cytoskeleton remodeling to facilitate leishmanial 
parasite phagocytosis in the macrophages and reduces disease associated lesions 
[91]. Another signaling pathway inhibitor, AS-605240 (PI3K gamma inhibitor) 
has shown to be as efficacious as sodium stibogluconate (SSG) in the treating of L. 
mexicana infection [92]. Similarly, another PI3K inhibitor CAL-101 and IC87114 are 
known to effectively reduce parasitic burden by reducing the B-cells and regulatory 
T-cells populations [93, 94]. Another tyrosine kinase inhibitor, ibrutinib has been 
shown to treat leishmaniasis by triggering TH1-polarized IFN-γ production [95]. 
Tellurium based immunomodulator (AS101) has shown to effectively revert t-cell 
anergy and promote NO production while inhibiting IL-10 signaling in L. don-
ovani infection. In Chagas disease, inhibitors of GPCRs provide protection against 
the disease by preventing the parasite entry and infection [96]. Parasite derived 
thromboxane A2 signaling induces apoptosis, vasoconstriction and disease associ-
ated cardiomyopathy thus use of SQ29548, thromboxane A2 receptor antagonist 
abrogates the T. cruzi infection [97]. Conversely, platelet activating factor and 
leukotriene B4 induces NO production and effectively controls the parasite [98, 99]. 
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Further, β-adrenergic receptor blockade along with carvedilol has been an effective 
strategy to improve clinical symptom of Chagas cardiomyopathy [100].
Tyrosine kinase inhibitors (lapatinib) have proven their efficacies in controlling 
Human African Trypanosomiasis (HAT) pathogenesis by blocking parasite endocy-
tosis [101]. Furthermore, PI3Kγ/mTOR signaling inhibitors as NVP-BEZ235 restricts 
the T. brucei infection [102]. Lectin based therapy using parasite galactose-N-acetyl-
d-galactosamine inhibitable lectin (Gallectin) instigates IL-12 production from DCs, 
T-cell proliferation and IFN-γ production [103].
Rosiglitazone, peroxisome proliferator-activator receptor gamma (PPARγ) 
agonist, is known to enhance phagocytic clearance of parasitized erythrocytes and 
reduce parasitic burden in malaria by inhibiting the mitogen-activated protein 
kinase (MAPK) and NF-κB signaling [104].
In helminthic infection (Strongyloidiasis), anakinra (IL-1β receptor antagonist) 
potentially improved innate cytokine responses (IL-33 and IL-25) eventually 
causing parasite expulsion [105]. Therefore, small molecular have shown potential 
therapeutic benefits in parasitic infection, here is just the tip of huge iceberg, 
research is underway to explore other molecules.
3.3 Nano-medicinal approach
The application of nanomaterials in the field of medicine for diagnosis and treat-
ment received considerable attention in recent decades for parasitic diseases. The 
diagnostic potential of nanomaterials has been seen in malaria [106, 107], toxoplas-
mosis [108], cryptosporiodiosis [109], amebiasis [110] and leishmaniasis [111, 112].
Considering the nanoparticles as treatment option for parasitic diseases, these 
particles have proven efficacy in targeting the infected macrophages for treatment 
of VL [113]. Silver alone or in combination with chitosan nanoparticles exhibited 
anti-toxoplasma effects by exacerbating serum IFN-γ levels and lowering the 
parasitic burden [114]. Spiramycin loaded chitosan nanoparticles have shown to 
effectively treat toxoplasmosis [115]. In giardiasis, combination nanotherapy with 
silver, chitosan and curcumin nanoparticles have been shown to effectively clear 
the parasites from intestine and stool without any adverse effects [116]. Chitosan 
as nanosuspension has also shown lethal effects on Cryptosporidium oocysts [117]. 
Similarly, silver nanoparticles have also been shown to effectively reduced oocyst 
burden by triggering IFN-γ, without any adverse events as seen with standard 
therapeutic options [118].
The biodegradability and non-immunogenic properties of nanoparticles have 
made them suitable as delivery agents for drugs and vaccines. Nanoformulation 
of recombinant P. falciparum protein (Pfs25H) served as transmission blocking 
vaccine for malaria, by abrogating the parasite infectivity to mosquitoes. Similarly, 
polymeric vaccine using polymer poly(lactide-co-glycoside) acid (PLGA) nanopar-
ticles with malaria antigen, VMP001, and immunostimulatory monophosphoryl 
A (MPL-A) triggered antigen-specific immune responses against P. vivax [119]. 
Furthermore, iron oxide nanoparticle conjugated with recombinant merozoite 
surface protein 1 (rMSP1) were efficiently engulfed by macrophages and DCs, 
that eventually triggered the pro-inflammatory responses [120]. In VL, conjuga-
tion of quercetin with gold nanoparticle [121], doxorubicin along with chitosan 
[122], amphotericin B as chitosan nanocapsule [123] and mannose-chitosan based 
nanoformulation of rifampicin served as effective delivery system for VL manage-
ment [124]. Chitosan/poly (vinyl alcohol) based microspheres has also shown to 
abrogate the Cryptosporidium sporozoites attachment to the enterocytes thus served 
as potential oral chemotherapy for Cryptosporidium infection [125].
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For helminthic infections, chitosan based albendazole formulation skewed the 
T-cell responses to TH1 type and reduced the parasitic burden, which led to parasite 
clearance in echinococcosis [126, 127] as well as in toxocariasis [128]. Similarly, silver 
assembled on fungal (Trichoderma harzianum) cell wall in the form of nanoformula-
tion improved the anti-fascioliasis potential of triclabendazole [129]. Liposomal 
nanoformulations (nanoparticles and nanocapsules) have been widely used for 
enhancing the efficacies and bioavailability of oral drugs for disease intervention. 
These formulations have gained significance as nanocarriers in helminthic infection 
due to their ability to diffuse through the intestinal mucosal layers. In schistosomiasis, 
liposome encapsulated praziquantel has shown significant reductions in parasitic 
burdens and hepatic granulomas due to increased affinity for parasite phospholipids 
[130]. Liposome based nanocapsules of praziquantel (PZQ-LNCs) improved the drug 
efficacy and ameliorated disease pathology [131]. Further, liposomal nanocapsules of 
miltefosine exerted potential schistosomal effects by ameliorating hepatic histology 
(reducing the granuloma size, number and inflammation) in single dose [132].
Nanoformulation has also been used for vaccine development and as adjuvants, 
self-assembling protein nanoparticles (SAPN) have shown to trigger protective 
antibodies and long-lived memory responses to confer sterile protection against 
malarial parasites (P. berghei and P. falciparum) [133]. SAPNs have also been used 
for delivering the epitopes to induce CD4+ and CD8+ T-cell responses against 
Toxoplasma gondii [134]. Archaea based nanoformulations (archaeosomes) have 
been used as adjuvant as a part of prophylactic vaccine against T. cruzi, instigated 
humoral as well as cell-mediated immune responses (TH1 responses) leading to 
marked reduction in parasitic burdens [135]. Cationic solid lipid nanoparticles 
have been successfully used as adjuvant as part of prime-boost strategy to reduce 
the parasitic burdens during VL. The vaccination triggered IFN-γ production, NO 
production and high levels of immunoglobulins (IgG1 and IgG2a) [136]. Therefore, 
nanoparticles served as viable, safe and effective vaccine platform as well as devel-
opment of molecular medicine for cost effective vaccine delivery.
4. Conclusion
In this world where cost of developing medicine for parasitic infections remain 
the greatest challenge, drug developers are embracing molecular medicine approach 
that promises to deal with the parasitic infections and improves the chances of suc-
cessful treatment. Molecular medicine has revolutionized the field of drug discov-
ery/development however, there are significant hurdles in turning the promise into 
reality. Perhaps, gradually but it is shaping the future of medicine with the help of 
molecular platforms, better bioinformatics services and better pharmacogenomic 
analyses has greatly facilitated the scientific community and the stakeholders to 
come on common platform to fight against the parasitic diseases.
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